drugset / Trial / NCT00046696
A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A study for patients who have failed standard therapy. If there is no dose limiting toxicities the patients will receive further cycles of therapy if there is no evidence of disease progression.
Timeline
- Start
- 2001-05
- Primary completion
- 2006-10
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NM-3 | Unknown | — | Oral |